ALNY
Earnings beat? Cute. Guidance cut? That’s the headline.
Alnylam came out with a pretty solid Q2 on paper: adjusted earnings of $1.84 a share topped expectations, and revenue jumped 67% year over year to $1.291 billion. But markets are picky little creatures, and they zeroed in on the part where management trimmed its full-year 2026 outlook.
The thing investors actually care about
The company said its TTR product sales guidance now sits at $5.275 billion to $5.725 billion, down from the earlier $5.30 billion to $5.80 billion range. Not a dramatic haircut on the surface, but enough to make the stock fall off a cliff because the explanation matters: Amvuttra’s second-line growth is normalizing after an initial burst of pent-up demand.
In plain English, Alnylam is basically saying, “The first wave of people who were waiting for this drug already got it.” That’s not the same as a disaster, but it is the kind of wording that makes growth investors clutch their oat milk.
Why this hits harder than a standard miss
Amvuttra is the star of the show here, pulling in $1.012 billion in global net product revenue for the quarter. Onpattro added another $18 million, which is nice, but not exactly moving-the-needle territory. The worry is that the ATTR-CM market may be maturing faster than bulls hoped, which is awkward timing when competitors like Ionis and AstraZeneca just stumbled in their own trial work.
Meanwhile, Alnylam also reiterated confidence in its Nucresiran program, which is the company’s way of reminding everyone that the story isn’t over. But after a 29% plunge and a fresh 52-week low, the message from Wall Street is pretty loud: show me the next leg of growth, not just the first leg of the launch.
Big picture
This is what happens when a high-flying biotech stops being a pure “beat and raise” machine. The drugs are still selling. The growth is still there. But the market wanted a longer runway, and Alnylam just told everyone the runway might be a little shorter than expected.